MEDICURE
SpecialtyMEDICURE is a specialty pharmaceutical company focused on Cardiovascular, Dermatology. Key products include ZYPITAMAG.
MEDICURE's Key Drugs
MEDICURE's core commercial portfolio centers on ZYPITAMAG, spanning Cardiovascular and Dermatology — its most strategically important drugs approved in the last 15 years.
MEDICURE's Recent FDA Approvals
New NDA/BLA approvals for MEDICURE over the last two years — novel drugs only, excluding generics and label supplements.
MEDICURE's Therapeutic Areas
MEDICURE's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Dermatology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MEDICURE's Top Competitors
MEDICURE's closest competitors by therapeutic-area and drug-target overlap include Baxter, Bayer, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MEDICURE Pipeline Snapshot
MEDICURE has 2 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 2 Phase 2 and 0 Phase 1.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ZYPITAMAG leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1998-05-14
- Latest
- 2024-01-31
- Applications
- 3